PORTFOLIO COMPANIES
PORTFOLIO COMPANIES
Over 50 Successful Trade Sales and IPO's
PORTFOLIO COMPANIES
PORTFOLIO COMPANIES
Over 50 Successful Trade Sales and IPO's
1
Current Portfolio
Past Portfolio
 
 
  • Acusphere, USA
    Acusphere, USA

    Microparticle drug delivery

    Acusphere was listed on NASDAQ in 2003.

  • Adnexus Therapeutics, USA
    Adnexus Therapeutics, USA

    Next-generation biologics

    Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.

  • Agensys, USA
    Agensys, USA

    Antibody development

    Agensys was acquired by Astellas for up to $537 million in 2007.

  • Anadys Pharmaceuticals, USA
    Anadys Pharmaceuticals, USA

    Antivirals

    Anadys Pharmaceuticals was listed on NASDAQ in 2004.

  • Anthera, USA
    Anthera, USA

    Drug development cardiovascular

    Anthera was listed on NASDAQ in 2010. 

  • Arpida, Switzerland
    Arpida, Switzerland

    Antibacterials

    Arpida was listed on SIX Swiss Exchange in 2005.

  • Aspreva, Canada
    Aspreva, Canada

    Specialty pharma

     Axovan was acquired by Actelion in 2004.

  • Asthmatx, USA
    Asthmatx, USA

    Medical device Asthma treatment

    Asthmatx was sold to Boston Scientific for up to $443 million in 2010. 

  • Axovan, Switzerland
    Axovan, Switzerland

    Drug development cardiovascular

    Axovan was acquired by Actelion in 2004.

  • Barofold, USA
    Barofold, USA

    Protein folding technology

    BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.

  • Basilea Pharmaceutica, Switzerland
    Basilea Pharmaceutica, Switzerland

    Antibiotics and antifungals

    Position was sold in 2015. 

  • BioControlMedical, Switzerland/Israel
    BioControlMedical, Switzerland/Israel

    Neurostimulation devices

    BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system. BioControl Medical has focused on the development of the CardioFit® System for the treatment of heart failure via direct vagus nerve stimulation.

  • Biovitrum, Sweden
    Biovitrum, Sweden

    Protein manufacturing

    Biovitrum was listed on OMX Stockholm in 2006.

  • Brahms, Germany
    Brahms, Germany

    Specialty diagnostics

    Brahms was sold to ThermoFischer for $470 million in 2009.

  • Cardion, Germany
    Cardion, Germany

    Drug discovery inflammation

    Cardion was sold to Roche in 2003.

  • ChemoCentryx, USA
    ChemoCentryx, USA

    Drug development inflammation

    ChemoCentryx was listed on NASDAQ in 2012.

  • China Nuokang, China
    China Nuokang, China

    Specialty pharma

    China Nuokang was listed on NASDAQ in 2009.

  • Corgentech, USA
    Corgentech, USA

    Pain therapeutics

    Corgentech was listed on NASDAQ in 2004.

  • Cytokinetics, USA
    Cytokinetics, USA

    Drug development oncology

    Cytokinetics was listed on NASDAQ in 2004.

  • Cytos Biotechnology, Switzerland
    Cytos Biotechnology, Switzerland

    Immunotherapy

    Cytos was listed on SIX Swiss Exchange in 2002.

  • Delenex Therapeutics, Switzerland
    Delenex Therapeutics, Switzerland

    Antibody Technologies

    Delenex was acquired by Cell Medica in 2016.

  • Ellipse Technologies, USA
    Ellipse Technologies, USA

    Adjustable orthopedic implants

    Merger with NuVasive (Nasdaq: NUVA) in 2016.

  • Esbatech, Switzerland
    Esbatech, Switzerland

    Next-generation anti-bodies

    Esbatech was acquired by Alcon (Novartis) for $150 million in cash plus contingent payments of up to $439 million. 

  • Gemin X, Canada
    Gemin X, Canada

    Drug development oncology

    Gemin X was acquired by Cephalon for $225 million in 2003.

  • Icagen, USA
    Icagen, USA

    Inflammation

    Icagen was listed on NASDAQ in 2004.

  • Infinity Pharmaceuticals, USA
    Infinity Pharmaceuticals, USA

    Inflammation

    Infinity Pharmaceuticals was listed on NASDAQ in 2006. 

  • Kolltan Pharmaceuticals, USA
    Kolltan Pharmaceuticals, USA

    Drug development oncology

    Kolltan Pharmaceuticals, Inc. is developing novel monoclonal antibody  drugs targeting receptor tyrosine kinases (RTKs).

  • Lifeline Scientific, USA
    Lifeline Scientific, USA

    Organ preservation for transplants

    Lifeline Scientific was listed on AIM London in 2008. 

  • Mediservice, Switzerland
    Mediservice, Switzerland

    Drug distribution

    Mediservice was sold to Galenica in 2007.

  • Micromet, Germany/USA
    Micromet, Germany/USA

    Antibody drug development

    Micromet was listed on NASDAQ in 2003. 

  • Micrus Endovascular, USA
    Micrus Endovascular, USA

    Treatment of brain aneurysms

    Micrus was listed on NASDAQ in 2005. 

  • Mpex, USA
    Mpex, USA

    Cystic fibrosis drugs

    Mpex was acquired by Axcan in 2011. 

  • mtm Laboratories, Germany
    mtm Laboratories, Germany

    Cervical cancer diagnostics

    mtm was sold to Roche for $185 million plus $85 million contingent payments in 2011. 

  • Newron Pharmaceuticals, Italy
    Newron Pharmaceuticals, Italy

    Neurology drugs

    Newron was listed on SIX Swiss Exchange in 2006.

  • Northstar Neurosciences, USA
    Northstar Neurosciences, USA

    Stroke rehabilitation

    Northstar was listed on NASDAQ in 2006. 

  • Ophthotech, USA
    Ophthotech, USA

    Drug development ophthalmology

    Position was sold in 2016.

  • Panomics, USA
    Panomics, USA

    Cellular assays

    Panomics was acquired by Affymetrix for $73 million in 2008.

  • PharmaSwiss, Switzerland
    PharmaSwiss, Switzerland

    Specialty pharma

    PharmaSwiss was acquired by Valeant for €350 million in 2009. 

  • Precimed, Switzerland/USA
    Precimed, Switzerland/USA

    Surgical instruments

    Precimed was sold to GreatBatch for $125 million in 2008.

  • PTC
    PTC

    Drug development orphan diseases

    Position was sold in 2016. 

  • Renovis, USA
    Renovis, USA

    Neurology

    Renovis was listed on NASDAQ in 2003.

  • SkyePharma, U.K.
    SkyePharma, U.K.

    Drug delivery

    Merger with Vectura Group plc (LSE: VEC) in 2016.

  • Sloning BioTechnology, Germany
    Sloning BioTechnology, Germany

    Protein libraries

    Sloning was sold to Morphosys in 2010.

  • Sunesis Pharmaceuticals, USA
    Sunesis Pharmaceuticals, USA

    Drug Development, Genetic Diseases

     

  • Swedish Orphan Biovitrum (SOBI), Sweden
    Swedish Orphan Biovitrum (SOBI), Sweden

    Oncology drug development

    Position was sold in 2015.

  • Syntonix, USA
    Syntonix, USA

    Hemophilia

    Syntonix was acquired by Biogen Idec for up to $120 million in 2007.

  • Syrrx, USA
    Syrrx, USA

    Metabolic diseases

    Syrrx was acquired by Takeda for $270 million in 2005. 

  • Transform Pharmaceuticals, USA
    Transform Pharmaceuticals, USA

    Drug formulations

    Transform was acquired by Johnson & Johnson for $230 million in 2005.

  • True North Therapeutics
    True North Therapeutics

    Orphan Diseases

    True North Therapeutics was acquired by Bioverativ in 2017.  

  • Xenoport, USA
    Xenoport, USA

    Neurology

    Xenoport was listed on NASDAQ in 2005. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone +41 43 888 7171